Skip to main content
main-content

memo - Magazine of European Medical Oncology OnlineFirst articles

09.05.2022 | short review

Essential news and practice changing trials in oesophageal, gastroesophageal junction and gastric cancer in 2021

In this short review we aim to summarize the highlights in gastric, gastroesophageal junction and oesophageal cancer in 2021. We will discuss practice changing studies and potential guideline changes based on these trials, with focus on the latest …

verfasst von:
Patrick Reimann, Thomas Winder

Open Access 13.04.2022 | review

Applicability of ESMO-MCBS and ESCAT for molecular tumor boards

Scoring systems for classifying genomic alterations (GAs) with respect to their potential targeted anticancer therapies (TTs) may be useful for rational and evidence-based decision-making, for example in molecular tumor boards. Therefore, a …

verfasst von:
Dr.med.univ. Ladislaia Wolff, Ap. Prof. PD Dr. Dr. Barbara Kiesewetter

Open Access 12.04.2022 | short review

Radiotherapy update: current role of radiotherapy in the treatment of lymphomas

Radiotherapy (RT) remains an important modality in the modern treatment of lymphomas. In Hodgkin lymphoma (HL), its role is stage-dependent. In early stage favorable HL, RT is an essential component of combined treatment. In early unfavorable and …

verfasst von:
MD Cora Waldstein

Open Access 15.02.2022 | short review

Molecular profiling leading to personalized treatment in breast cancer

With the development of various targeted therapies in breast cancer, detection of biomarkers for predicting treatment efficacy gains importance. With the definition of intrinsic subtypes, breast cancer has paved the way for personalized treatment.

verfasst von:
Dr. med. univ. Eva Valentina Klocker, Assoz. Prof. PD Dr. med. univ. et scient. med. Marija Balic, Univ.-Prof. Dr. Günther Steger

08.06.2021 | case report

Breast implant-associated anaplastic large-cell lymphoma: a European case report and literature review

Breast implant-associated anaplastic large-cell lymphoma (BIA-ALCLC) is an infrequent T‑cell neoplasm that accounts for approximately 3% of non-Hodgkin lymphomas. After the first case of BIA-ALCL, an increasing number of scientific works …

verfasst von:
M.D. Federico Ghidinelli, M.D. Luigi Filippini, M.D. Paola Porsio, M.D. Federico Canzi, M.D. Rino Balzano, M.D. Elisa Flocchini, M.D. Anna Bianchi

13.10.2020 | original report

WNT3 and LEF1 as markers for diagnosis and survival prediction in chronic lymphocytic leukemia patients

Chronic lymphocytic leukemia (CLL) is a B-cell malignancy characterized by clonal expansion and accumulation of mature B‑lymphocytes in peripheral blood, bone marrow, and secondary lymphoid tissues [ 1 ]. CLL is highly heterogeneous where some …

verfasst von:
Manal Atef, MD/PhD Layla M. Saleh, Noha Eisa, Sameh Shamaa